David G Strauss
Overview
Explore the profile of David G Strauss including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
163
Citations
2902
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gershuny V, Florian J, van der Schrier R, Davis M, Salcedo P, Wang C, et al.
Br J Anaesth
. 2025 Feb;
PMID: 39986981
Background: Benzodiazepines can exacerbate opioid-induced respiratory depression by furthering the decrease in central respiratory drive and causing loss of upper airway patency potentially leading to airway obstruction. This study aimed...
2.
Loewenstein D, Wieslander B, Heiberg E, Axelsson J, Klem I, Nijveldt R, et al.
Eur Heart J Cardiovasc Imaging
. 2024 Nov;
26(3):435-443.
PMID: 39576753
Aims: More than 90% of patients with left bundle branch block (LBBB) and reduced left ventricular (LV) ejection fraction have LV dyssynchrony and a high probability of response to cardiac...
3.
Satsuka A, Ribeiro A, Kawagishi H, Yanagida S, Hirata N, Yoshinaga T, et al.
J Pharmacol Toxicol Methods
. 2024 Jun;
128:107530.
PMID: 38917571
Introduction: Cardiac safety assessment, such as lethal arrhythmias and contractility dysfunction, is critical during drug development. Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) have been shown to be useful in...
4.
van Lemmen M, Florian J, Li Z, van Velzen M, van Dorp E, Niesters M, et al.
Anesthesiology
. 2024 Feb;
140(4):857-859.
PMID: 38335033
No abstract available.
5.
Strauss D, Li Z, Chaturbedi A, Chakravartula S, Samieegohar M, Mann J, et al.
JAMA Netw Open
. 2024 Jan;
7(1):e2351839.
PMID: 38261323
Importance: Questions have emerged as to whether standard intranasal naloxone dosing recommendations (ie, 1 dose with readministration every 2-3 minutes if needed) are adequate in the era of illicitly manufactured...
6.
Wu W, Choe M, Johannesen L, Vicente J, Bende G, Stockbridge N, et al.
Clin Pharmacol Ther
. 2023 Sep;
114(6):1332-1341.
PMID: 37702218
Current cardiac safety testing focuses on detecting drug-induced QT prolongation as a surrogate for risk of Torsade de Pointes. The nonclinical strategy, described in International Conference on Harmonization (ICH) S7B,...
7.
Arefin A, Mendoza M, Dame K, Garcia M, Strauss D, Ribeiro A
Front Pharmacol
. 2023 Jul;
14:1212092.
PMID: 37469866
Engineered heart tissues (EHTs) are three-dimensional culture platforms with cardiomyocytes differentiated from human pluripotent stem cells (hPSCs) and were designed for assaying cardiac contractility. For drug development applications, EHTs must...
8.
van Lemmen M, Florian J, Li Z, van Velzen M, van Dorp E, Niesters M, et al.
Anesthesiology
. 2023 Jul;
139(3):342-353.
PMID: 37402248
Opioids are effective analgesics, but they can have harmful adverse effects, such as addiction and potentially fatal respiratory depression. Naloxone is currently the only available treatment for reversing the negative...
9.
Chiu K, Racz R, Burkhart K, Florian J, Ford K, Garcia M, et al.
Front Med (Lausanne)
. 2023 Feb;
9:1109541.
PMID: 36743666
The U.S. Food and Drug Administration (FDA) Division of Applied Regulatory Science (DARS) moves new science into the drug review process and addresses emergent regulatory and public health questions for...
10.
De Palma R, Patel V, Florian J, Keire D, Selaya D, Strauss D, et al.
J Pharm Sci
. 2023 Feb;
112(5):1315-1323.
PMID: 36736776
Control of N-nitrosoamine impurities is important for ensuring the safety of drug products. Findings of nitrosamine impurities in some drug products led FDA to develop new guidance providing recommendations for...